BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20618329)

  • 21. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
    Wen YJ; Barlogie B; Yi Q
    Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma.
    Cohen S; Haimovich J; Hollander N
    J Immunol; 2009 Feb; 182(3):1667-73. PubMed ID: 19155516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
    Wang S; Hong S; Wezeman M; Qian J; Yang J; Yi Q
    Front Biosci; 2007 May; 12():3566-75. PubMed ID: 17485322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
    Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
    Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
    Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
    Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
    Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
    Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
    Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
    Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
    Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
    Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
    Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
    Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
    Hájek R; Butch AW
    Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
    Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
    Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.
    Gilliet M; Kleinhans M; Lantelme E; Schadendorf D; Burg G; Nestle FO
    Blood; 2003 Jul; 102(1):36-42. PubMed ID: 12560234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
    Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ
    J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
    Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T
    Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.